BÖLEK, H. Et Al. 2025. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium. Cancer Communications , vol.45, no.5 , 572-576.

BÖLEK, H., Kuzu, O. F., Sertesen Camoz, E., Sim, S., Sekmek, S., Karakas, H., ... Isık, S.(2025). Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium. Cancer Communications , vol.45, no.5, 572-576.

BÖLEK, HATİCE Et Al. "Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium," Cancer Communications , vol.45, no.5, 572-576, 2025

BÖLEK, HATİCE Et Al. "Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium." Cancer Communications , vol.45, no.5, pp.572-576, 2025

BÖLEK, H. Et Al. (2025) . "Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium." Cancer Communications , vol.45, no.5, pp.572-576.

@article{article, author={HATİCE BÖLEK Et Al. }, title={Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium}, journal={Cancer Communications}, year=2025, pages={572-576} }